The notes issued include $1.25 billion of 4.650% senior notes due 2028, $1 billion of 4.875% senior notes due 2030, $1 billion of 5.200% senior notes due 2035, and $750 million of 5.600% senior notes due 2055. These debt securities were offered under a shelf registration statement that was filed on February 14, 2025, and the terms of the notes were described in a prospectus supplement filed on February 20, 2025. This new issuance adds to AbbVie's existing total debt of $68 billion, with InvestingPro analysis showing the company's current ratio at 0.66. AbbVie's newly issued notes are unsecured and unsubordinated, ranking equally with the company's existing and future unsecured, unsubordinated indebtedness. The notes will mature on March 15 of their respective years, and AbbVie retains the option to redeem the notes at specified times prior to their maturity dates, at prices outlined in the indenture. The indenture, which governs the notes, includes customary terms and covenants.